Claims for Patent: 10,016,434
✉ Email this page to a colleague
Summary for Patent: 10,016,434
Title: | Methods for the treatment of HER2 amplified cancer |
Abstract: | Described herein are methods and compositions for treating HER2-amplified cancer. The methods include administering to an individual in need thereof ibrutinib. |
Inventor(s): | Chen; Jun (San Jose, CA), Buggy; Joseph J. (Mountain View, CA), Elias; Laurence (Berkeley, CA) |
Assignee: | Pharmacyclics LLC (Sunnyvale, CA) |
Application Number: | 15/652,470 |
Patent Claims: | 1. A method for treating HER2 amplified cancer in an individual in need thereof, wherein the cancer is selected from the group consisting of colon, lung, and pancreatic
cancers, and the method comprises administering to the individual in need thereof a composition comprising 1-(R)-(3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)pi- peridin-1-yl)prop-2-en-1-one ##STR00018## or a pharmaceutically
acceptable salt thereof.
2. The method of claim 1, wherein the HER2-amplified cancer is metastatic. 3. The method of claim 1, wherein the HER2-amplified cancer has a HER2:CEP17 ratio of 2.2-4.0 or >4.0. 4. The method of claim 1, wherein the HER2-amplified cancer is refractory to treatment. 5. The method of claim 1, further comprising co-administering an additional therapeutic agent. 6. The method of claim 5, wherein the additional therapeutic agent is an anti-HER2 therapeutic agent, a pan-ErbB inhibitor, or an anti-VEGF therapeutic agent. 7. The method of claim 6, wherein the anti-HER2 therapeutic agent is selected from the group consisting of trastuzumab, trastuzumab emtansine, pertuzumab, lapatinib, and MM-111. 8. The method of claim 6, wherein the pan-ErbB inhibitor is selected from the group consisting of afatinib, neratinib, and dacomitinib. 9. The method of claim 6, wherein the anti-VEGF therapeutic agent is selected from the group consisting of bevacizumab, ranibizumab, lapatinib, sunitinib, sorafenib, axitinib, and pazopanib. 10. The method of claim 5, wherein the additional therapeutic agent is selected from the group consisting of: temsirolimus; paclitaxel; ASLAN001; vorinostat; doxorubicin; cyclophosphamide; cisplatin; docetaxel; dasatinib; trastuzumab and docetaxel; pertuzumab and docetaxel; doxorubicin, cyclophosphamide and paclitaxal; and doxorubicin, cyclophosphamide and fluorouracil. 11. The method of claim 1, wherein the HER2-amplified cancer is colon cancer. 12. The method of claim 1, wherein the HER2-amplified cancer is lung cancer. 13. The method of claim 1, wherein the HER2-amplified cancer is pancreatic cancer. 14. The method of claim 1, wherein the composition comprises ibrutinib. |
Details for Patent 10,016,434
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Genentech, Inc. | HERCEPTIN | trastuzumab | For Injection | 103792 | 09/25/1998 | ⤷ Try a Trial | 2033-08-12 |
Genentech, Inc. | HERCEPTIN | trastuzumab | For Injection | 103792 | 02/10/2017 | ⤷ Try a Trial | 2033-08-12 |
Genentech, Inc. | AVASTIN | bevacizumab | Injection | 125085 | 02/26/2004 | ⤷ Try a Trial | 2033-08-12 |
Genentech, Inc. | LUCENTIS | ranibizumab | Injection | 125156 | 06/30/2006 | ⤷ Try a Trial | 2033-08-12 |
Genentech, Inc. | LUCENTIS | ranibizumab | Injection | 125156 | 08/10/2012 | ⤷ Try a Trial | 2033-08-12 |
Genentech, Inc. | LUCENTIS | ranibizumab | Injection | 125156 | 10/13/2016 | ⤷ Try a Trial | 2033-08-12 |
Genentech, Inc. | LUCENTIS | ranibizumab | Injection | 125156 | 03/20/2018 | ⤷ Try a Trial | 2033-08-12 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.